HPGC Renmintongtai Pharmaceutical Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Weidong Zhu
Chief executive officer
CN¥1.2m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 9.8yrs |
| CEO ownership | n/a |
| Management average tenure | 2.8yrs |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
HPGC Renmintongtai Pharmaceutical Corporation's (SHSE:600829) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 15
Is HPGC Renmintongtai Pharmaceutical (SHSE:600829) A Risky Investment?
Oct 01HPGC Renmintongtai Pharmaceutical (SHSE:600829) Might Be Having Difficulty Using Its Capital Effectively
Sep 05CEO
Weidong Zhu (55 yo)
9.8yrs
Tenure
CN¥1,232,100
Compensation
Mr. Weidong Zhu served as Deputy General Manager at HPGC Renmintongtai Pharmaceutical Corporation. Mr. Zhu serves as Deputy General Manager and General manager of Harbin Renmintongtai Pharmacy chain stores...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman | no data | CN¥1.23m | no data | |
| Deputy GM & CFO | 2.7yrs | CN¥645.00k | no data | |
| Deputy GM & Director | no data | CN¥985.00k | no data | |
| Board Secretary | 2.8yrs | CN¥217.20k | no data | |
| Chief Accountant | 9.8yrs | CN¥176.80k | no data |
2.8yrs
Average Tenure
55yo
Average Age
Experienced Management: 600829's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman | 9.8yrs | CN¥1.23m | no data | |
| Deputy GM & Director | no data | CN¥985.00k | no data | |
| Chairman of the Supervisory Board | 2.4yrs | no data | no data | |
| Independent Director | 5.4yrs | CN¥80.00k | no data | |
| Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data |
1.7yrs
Average Tenure
54yo
Average Age
Experienced Board: 600829's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:30 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HPGC Renmintongtai Pharmaceutical Corporation is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xian Chao Zhang | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Hai Zhu Peng | Huatai Research |
| Yin Ye | Ping An Securities Co. Ltd. |